Compare PHAT & ASIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | ASIC |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | 203 |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 930.6M |
| IPO Year | 2019 | N/A |
| Metric | PHAT | ASIC |
|---|---|---|
| Price | $10.66 | $19.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $19.50 | ★ $26.75 |
| AVG Volume (30 Days) | ★ 986.1K | 103.1K |
| Earning Date | 04-30-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $92.15 | $35.31 |
| Revenue Next Year | $59.79 | $34.70 |
| P/E Ratio | ★ N/A | $98.60 |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $16.35 |
| 52 Week High | $18.31 | $23.88 |
| Indicator | PHAT | ASIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 42.09 |
| Support Level | $10.06 | $17.91 |
| Resistance Level | $12.77 | $19.30 |
| Average True Range (ATR) | 0.68 | 0.71 |
| MACD | 0.10 | -0.29 |
| Stochastic Oscillator | 33.87 | 0.96 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.